Media Articles Related to Ceprotin (Protein C)
Protein chatter to blame for cystic fibrosis
Source: Cystic Fibrosis News From Medical News Today [2015.12.01]
Irrelevant chatter among proteins appears to underlie cystic fibrosis; the discovery offers hope for a solution to the life-threatening condition.
A new player revealed in nerve growth process
Source: Stroke News From Medical News Today [2016.04.21]
Role of adaptor protein CD2AP in neuron sprouting discovered by UofL researchers could lead to therapies for Alzheimer's disease, stroke recovery and spinal cord injury.
Cartilage protein may contribute to the development of breast cancer
Source: Bones / Orthopedics News From Medical News Today [2016.04.13]
Research from Lund University in Sweden shows that the protein COMP, which mainly exists in cartilage, can also be found in breast cancer tumours in patients with a poor prognosis.
How a metabolic pathway promotes breast cancer metastasis
Source: Breast Cancer News From Medical News Today [2016.04.07]
A metabolic pathway that is up-regulated in certain breast cancers promotes the disease's progression by activating a cell signaling protein called Arf6, according to a paper published in the...
Lymphoma overrides a key protein's quadruple locks
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.03.22]
Protein chemists at Johns Hopkins report they are closer to explaining why certain blood cancers are able to crack a molecular security system and run rampant.
Published Studies Related to Ceprotin (Protein C)
Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. [2011.09]
Chronic wounds arising from orthopedic surgery present a major clinical challenge. Osteomyelitis may develop from polymicrobial infection, which can be unresponsive to treatment and lead to amputation...
A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. [2011.08]
OBJECTIVE: To investigate the association between markers of acute endothelial glycocalyx degradation, inflammation, coagulopathy, and mortality after trauma. BACKGROUND: Hyperinflammation and acute coagulopathy of trauma predict increased mortality. High catecholamine levels can directly damage the endothelium and may be associated with enhanced endothelial glycocalyx degradation, evidenced by high circulating syndecan-1... CONCLUSIONS: In trauma patients, high circulating syndecan-1, a marker of endothelial glycocalyx degradation, is associated with inflammation, coagulopathy and increased mortality.
Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. [2011.04.15]
RATIONALE: Patients with acute lung injury have impaired function of the lung surfactant system. Prior clinical trials have shown that treatment with exogenous recombinant surfactant protein C (rSP-C)-based surfactant results in improvement in blood oxygenation and have suggested that treatment of patients with severe direct lung injury may decrease mortality. OBJECTIVES: Determine the clinical benefit of administering an rSP-C-based synthetic surfactant to patients with severe direct lung injury due to pneumonia or aspiration... CONCLUSIONS: In this study, rSP-C-based surfactant was of no clinical benefit to patients with severe direct lung injury. The unexpected lack of improvement in oxygenation, coupled with the results of in vitro tests, suggest that the administered suspension may have had insufficient surface activity to achieve clinical benefit.
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. 
INTRODUCTION: There are no published data on the status of endogenous activated protein C (APC) in pulmonary embolism (PE), and no data on the effect of drotrecogin alfa (activated) (DAA) given in addition to therapeutic dose enoxaparin... CONCLUSIONS: In patients with acute submassive PE endogenous APC levels are low. DAA infusion enhances the inhibition of fibrin formation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00191724.
Combination of activated protein C and topical negative pressure rapidly
regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic
Chronic wounds arising from orthopedic surgery present a major clinical
challenge. Osteomyelitis may develop from polymicrobial infection, which can be
unresponsive to treatment and lead to amputation...
Clinical Trials Related to Ceprotin (Protein C)
Ceprotin Treatment Registry [Completed]
Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock. [Recruiting]
The purpose of this study is to investigate the effects on systemic hemodynamics,
microcirculation and organ function of human Protein C concentrate in patients with sepsis
and septic shock.
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency [Completed]
The purpose of this study is to show that Protein C Concentrate is a safe and effective
treatment for subjects with congenital protein C deficiency. Depending on the type of
treatment required, patients are assigned to one of 3 study parts: Part 1 is for the
treatment of acute episodes, Part 2 is for short-term prophylaxis, and Part 3 is for
long-term prophylaxis in infants aged less than 6 months only.
Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND [Completed]
This is a data collection study with the purpose of capturing dosing and treatment outcome
data in subjects with severe congenital protein C deficiency who were treated with protein C
concentrate under an Emergency Use Investigational New Drug Application (IND).
Activated Protein C and Corticosteroids for Human Septic Shock [Completed]
This study aims at comparing the efficacy and safety of recombinant human activated protein
C to that of low dose of corticosteroids and at investigating the interaction between these
drugs in the management of septic shock